Equibles does not estimate personal net worth.
Get an email with a short summary when Vera Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get VERA alertsVera Therapeutics, Inc. reported in an 8-K filed January 8, 2024 that Robert M. Brenner, M.D. was appointed Chief Medical Officer, effective January 3, 2024. Robert M. Brenner, M.D. has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Vera Therapeutics, Inc. on November 10, 2026. Vera Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Vera Therapeutics, Inc. includes Marshall Fordyce (CEO and Board Member), Michael M. Morrissey, Ph.D. (Chairman and Board Member), Sean Grant (CFO) and 7 others.
“The Company appointed Dr. Robert M. Brenner, M.D., to succeed Dr. Lin as the Company’s Chief Medical Officer, effective January 3, 2024.”
“Rob, you want to start with the monthly program? Yeah. So, um... As Marshall shared, we really We celebrate the dosing profile that we provide today. Weekly, small-volume, auto-injectors, self-administered at home, used throughout the development program.”
“Having spent the past few years working to advance a tachycept through clinical development and U.S. regulatory approval, it is deeply rewarding to now see Trutacna reaching patients.”
SEC 8-K
2024-01-03–present
Biotechnology · Healthcare
